Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed

Aura Biosciences, Inc.

2026-Q1 EPS reported -$0.50

Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.
Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.
Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.
Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.
Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $33.7 million.

Period: the first quarter ended March 31, 2026
Net income: $33.7 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026, was $33.7 million, compared to $27.5 million for the three months ended March 31, 2025.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.